Author

S. Gamblin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 4 Assay:proteomics· 3 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

R. Harvey· 5 shared C. Swanton· 4 shared G. Kassiotis· 4 shared J. Mccauley· 4 shared N. Faulkner· 4 shared S. Gandhi· 4 shared S. Hussain· 4 shared H. Rickman· 3 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

R. Harvey

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1

G. Dowgier, A. Hobbs, D. Greenwood, M. Shawe-Taylor, P. Stevenson-Leggett, J. Bazire, R. Penn, R. Harvey, V. Libri, G. Kassiotis, S. Gamblin, N. S. Lewis, B. Williams, C. Swanton, S. Gandhi, , M. Y. Wu

The paper evaluates neutralising antibody titres against SARS-CoV-2 variant JN.1 using live-virus microneutralisation assays in vaccinated individuals, finding higher titres in monovalent vaccine recipients.

bioRxiv · Apr 17, 2024 · PreprintMicrobiology

Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination

K. Ng, N. Faulkner, K. Finsterbusch, M. Wu, R. Harvey, S. Hussain, M. Greco, Y. Liu, S. Kjaer, C. Swanton, S. Gandhi, R. Beale, S. Gamblin, P. Cherepanov, J. Mccauley, , G. Kassiotis

This study shows that SARS-CoV-2 S2-targeted vaccination induces broad neutralizing antibodies against multiple coronaviruses and provides better protection than homologous boosting.

bioRxiv · Nov 30, 2021 · PreprintImmunology

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

N. Faulkner, K. Ng, M. Wu, R. Harvey, S. Hussain, M. Greco, W. Bolland, S. Warchal, M. Margaritis, S. Paraskevopoulou, J. Heaney, H. Rickman, C. Houlihan, M. Spyer, D. Frampton, , G. Kassiotis

This study compares antibody cross-reactivity between SARS-CoV-2 B.1.1.7 and parental strains, finding reduced recognition and neutralization of older variants after B.1.1.7 infection.

bioRxiv · Mar 1, 2021Immunology

Favourable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases

C. Deakin, G. Cornish, K. Ng, N. Faulkner, W. Bolland, V. Panova, J. Hope, A. Rosa, R. Harvey, S. Hussain, C. Earl, B. Jebson, M. Wilkinson, L. Marshall, K. O'Brien, , G. Kassiotis

The paper examines antibody responses to HCoV-OC43 and SARS-CoV-2 in children with autoimmune rheumatic diseases, finding stronger spike antibody responses and cross-reactivity despite immunosuppressive treatment.

bioRxiv · Feb 15, 2021 · PreprintImmunology

Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans

K. W. Ng, N. Faulkner, G. Cornish, A. Rosa, R. Harvey, S. Hussain, R. Ulferts, C. Earl, A. Wrobel, D. Benton, C. Roustan, W. Bolland, R. Thompson, A. Agua-Doce, P. Hobson, , Mc

The paper identifies pre-existing and de novo humoral immunity to SARS-CoV-2 in humans, showing that uninfected individuals have SARS-CoV-2 S-reactive antibodies, particularly in children, and that infection leads to higher antibody titres targeting multiple subunits.

bioRxiv · May 14, 2020Immunology